Baidarbhi Chakraborty
Research Subjects
Baidarbhi Chakraborty has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Binita Goswami
Department of Biochemistry, Lady Hardinge Medical College, Delhi, New Delhi, India
3 shared publicationsGaurav Vishnoi
Department of Pharmacology, Maulana Azad Medical College, Delhi, New Delhi, India
3 shared publications- Binita Goswami
Department of Biochemistry, Maulana Azad Medical College, New Delhi, India
2 shared publications - Medha Rajappa
Department of Biochemistry, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India
2 shared publications - Surajeet Kumar Patra
Department of Biochemistry, Lady Hardinge Medical College, New Delhi, India
2 shared publications Suresh Kumar
Department of Medicine, Maulana Azad Medical College and Associated Lok Nayak Hospital, New Delhi-110002, India
2 shared publications
Latest Publications
- 31 October 2014
- Published by Wiley in Asia-Pacific Journal of Clinical Oncology
- Vol. 13 (5) , e402-e407
Interleukin‐6 gene‐174 G/C promoter polymorphism and its association with clinical profile of patients with multiple myeloma
Aim: In multiple myeloma (MM), the growth and survival of myeloma cells is controlled by interleukin‐6 (IL‐6), the plasma levels of which is controlled by a guanine/cytosine substitution occurring in position ‐174 of IL‐6 gene promoter region. We studied the occurrence of IL‐6‐174 G/C polymorphism in patients of MM and correlated the presence of genotypes with serum IL‐6 levels and tumor staging.Methods: One hundred three patients with MM and 117 age‐ and sex‐matched healthy controls were staged by International Staging System. IL‐6 genotypes were evaluated by polymerase chain reaction and restriction enzyme analysis. Serum levels of IL‐6 were assessed by enzyme‐linked immunosorbent assay.Results: Frequency of GG, GC and CC genotypes did not differ significantly between cases (GG 52%, GC 40%, CC 9%) and controls. The median serum level of IL‐6 was significantly higher among the GC genotype versus other genotypes (24 ng/mL, P = 0.007) as compared with the GG versus other genotypes (12 ng/mL, P = 0.001). GC was associated more with stage 3 disease (27%) than was GG (11%) or CC (22% P = 0.001).Conclusions: At position 174 of the IL‐6 promoter, patients with GC genotype had higher serum levels of IL‐6 and presented with more severe disease compared with patients with GG or CC genotype.
- 31 October 2014
- Published by Wiley in Asia-Pacific Journal of Clinical Oncology
- Vol. 13 (5) , e402-e407
Interleukin‐6 gene‐174 G/C promoter polymorphism and its association with clinical profile of patients with multiple myeloma
Aim: In multiple myeloma (MM), the growth and survival of myeloma cells is controlled by interleukin‐6 (IL‐6), the plasma levels of which is controlled by a guanine/cytosine substitution occurring in position ‐174 of IL‐6 gene promoter region. We studied the occurrence of IL‐6‐174 G/C polymorphism in patients of MM and correlated the presence of genotypes with serum IL‐6 levels and tumor staging.Methods: One hundred three patients with MM and 117 age‐ and sex‐matched healthy controls were staged by International Staging System. IL‐6 genotypes were evaluated by polymerase chain reaction and restriction enzyme analysis. Serum levels of IL‐6 were assessed by enzyme‐linked immunosorbent assay.Results: Frequency of GG, GC and CC genotypes did not differ significantly between cases (GG 52%, GC 40%, CC 9%) and controls. The median serum level of IL‐6 was significantly higher among the GC genotype versus other genotypes (24 ng/mL, P = 0.007) as compared with the GG versus other genotypes (12 ng/mL, P = 0.001). GC was associated more with stage 3 disease (27%) than was GG (11%) or CC (22% P = 0.001).Conclusions: At position 174 of the IL‐6 promoter, patients with GC genotype had higher serum levels of IL‐6 and presented with more severe disease compared with patients with GG or CC genotype.
- 1 October 2013
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 22 (7) , e159-e167
Lipoprotein(a), Ferritin, and Albumin in Acute Phase Reaction Predicts Severity and Mortality of Acute Ischemic Stroke in North Indian Patients
- 1 October 2013
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 22 (7) , e159-e167
Lipoprotein(a), Ferritin, and Albumin in Acute Phase Reaction Predicts Severity and Mortality of Acute Ischemic Stroke in North Indian Patients
- 1 July 2013
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 22 (5) , 683-689
Interleukin-6 Gene -174 G/C Promoter Polymorphism Predicts Severity and Outcome in Acute Ischemic Stroke Patients from North India
- 1 July 2013
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 22 (5) , 683-689
Interleukin-6 Gene -174 G/C Promoter Polymorphism Predicts Severity and Outcome in Acute Ischemic Stroke Patients from North India
- 7 July 2012
- Published by Elsevier in Clinical Biochemistry
- Vol. 45 (16-17) , 1541
Erratum to “Comparison of the various lipid ratios and indices for risk assessment in patients of myocardial infarction” [Clinical Biochemistry, Volume 45 (2012) 445–449]
- 7 July 2012
- Published by Elsevier in Clinical Biochemistry
- Vol. 45 (16-17) , 1541
Erratum to “Comparison of the various lipid ratios and indices for risk assessment in patients of myocardial infarction” [Clinical Biochemistry, Volume 45 (2012) 445–449]
- 30 April 2012
- Published by Elsevier in Clinical Biochemistry
- Vol. 45 (6) , 445-449
Comparison of the various lipid ratios and indices for risk assessment in patients of myocardial infarction
- 30 April 2012
- Published by Elsevier in Clinical Biochemistry
- Vol. 45 (6) , 445-449
Comparison of the various lipid ratios and indices for risk assessment in patients of myocardial infarction